175 related articles for article (PubMed ID: 18226004)
1. Tissue deposition of gadolinium and development of NSF: a convergence of factors.
Perazella MA
Semin Dial; 2008; 21(2):150-4. PubMed ID: 18226004
[TBL] [Abstract][Full Text] [Related]
2. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
Grobner T; Prischl FC
Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001
[TBL] [Abstract][Full Text] [Related]
3. [Nephrogenic systemic fibrosis].
Breitschaft A; Stahlmann R
Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P
J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720
[TBL] [Abstract][Full Text] [Related]
5. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?
Penfield JG; Reilly RF
Semin Dial; 2008; 21(2):129-34. PubMed ID: 18225999
[TBL] [Abstract][Full Text] [Related]
6. Current status of gadolinium toxicity in patients with kidney disease.
Perazella MA
Clin J Am Soc Nephrol; 2009 Feb; 4(2):461-9. PubMed ID: 19201920
[TBL] [Abstract][Full Text] [Related]
7. Dialytic therapies to prevent NSF following gadolinium exposure in high-risk patients.
Rodby RA
Semin Dial; 2008; 21(2):145-9. PubMed ID: 18226002
[TBL] [Abstract][Full Text] [Related]
8. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm.
Perazella MA
Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):519-25. PubMed ID: 19623065
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis: more questions and some answers.
Morcos SK; Thomsen HS
Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
[TBL] [Abstract][Full Text] [Related]
10. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
Lim YL; Lee HY; Low SC; Chan LP; Goh NS; Pang SM
Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041
[TBL] [Abstract][Full Text] [Related]
11. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.
Deo A; Fogel M; Cowper SE
Clin J Am Soc Nephrol; 2007 Mar; 2(2):264-7. PubMed ID: 17699423
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of NSF: New evidence challenging the prevailing theory.
Newton BB; Jimenez SA
J Magn Reson Imaging; 2009 Dec; 30(6):1277-83. PubMed ID: 19937925
[TBL] [Abstract][Full Text] [Related]
13. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
Andréjak M; Thuillier D; Lok C; Gras-Champel V
Therapie; 2007; 62(2):169-72. PubMed ID: 17582319
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic systemic fibrosis and gadolinium-based contrast: medico-legal implications.
Houck CM; Pristave RJ; Kannensohn KJ
Semin Dial; 2008; 21(2):166-70. PubMed ID: 18226003
[TBL] [Abstract][Full Text] [Related]
15. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.
High WA; Ayers RA; Chandler J; Zito G; Cowper SE
J Am Acad Dermatol; 2007 Jan; 56(1):21-6. PubMed ID: 17097388
[TBL] [Abstract][Full Text] [Related]
16. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review.
Idée JM; Port M; Medina C; Lancelot E; Fayoux E; Ballet S; Corot C
Toxicology; 2008 Jun; 248(2-3):77-88. PubMed ID: 18440117
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.
Abraham JL; Thakral C
Eur J Radiol; 2008 May; 66(2):200-7. PubMed ID: 18374532
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium use in patients with kidney disease: a cause for concern.
Perazella MA; Rodby RA
Semin Dial; 2007; 20(3):179-85. PubMed ID: 17555477
[TBL] [Abstract][Full Text] [Related]
19. Can the risk of gadolinium be extrapolated to lanthanum?
De Broe ME
Semin Dial; 2008; 21(2):142-4. PubMed ID: 18248522
[TBL] [Abstract][Full Text] [Related]
20. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.
Edward M; Quinn JA; Mukherjee S; Jensen MB; Jardine AG; Mark PB; Burden AD
J Pathol; 2008 Apr; 214(5):584-93. PubMed ID: 18220317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
